<DOC>
	<DOC>NCT01593787</DOC>
	<brief_summary>This study assessed the safety, tolerability, and efficacy of LCZ696 in hypertensive patients with renal dysfunction.</brief_summary>
	<brief_title>Safety and Tolerability and Efficacy of LCZ696 in Japanese Hypertensive Patients With Renal Dysfunction</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>LCZ 696</mesh_term>
	<criteria>Renal findings: Hypertensive patients with renal dysfunction and stable renal condition at least 4 weeks before screening visit. Satisfy office msSBP ≥140 mmHg and &lt;180 mmHg at baseline. Patients show msDBP ≥110 mmHg and/or msSBP ≥180 mmHg. History of angioedema, drugrelated or otherwise, as reported by the patient. Any other following renal disorder: Patients show eGFR &lt; 15mL/min/1.73m^2 Patients on dialysis Patients who previously entered a LCZ696 study and had been randomized or enrolled into the active drug treatment epoch. Other protocoldefined inclusion/exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Hypertension</keyword>
	<keyword>Renal dysfunction</keyword>
	<keyword>LCZ696</keyword>
</DOC>